Abstract
The accumulation of cancerous cells within a growing prostate tumor can deprive them of adequate vascular support. Without this support, the affected tumor cells become hypoxic, a condition that is usually unfavorable for the further growth and survival of eukaryotic cells. Mammalian cells, however, have the ability of responding to a hypoxic environment by activating a “hypoxia-response” signaling system. Ultimately, this signaling system upregulates the expression of a network of gene products that increase the propensity of the cell to survive even in this adverse environment. With increasing evidence that hypoxia and an activated hypoxia-response signaling system can influence progression (via increased angiogenic propensity and apoptotic resistance) and the therapeutic responsiveness of prostate cancer cells, this review will examine the concept of targeting hypoxia or the hypoxia-response system of prostate tumor cells as a means to suppress prostate tumor progression and metastasis or perhaps even as a means for eliminating prostate tumors in advanced prostate cancer patients
Keywords: prostate cancer, hypoxia, Hypoxia Inducible Factor, angiogenesis, vegf, apoptosis, akt/protein kinase b
Current Drug Targets
Title: Tumor Cell Hypoxia and the Hypoxia-Response Signaling System as a Target for Prostate Cancer Therapy
Volume: 4 Issue: 3
Author(s): Aristotelis G. Anastasiadis, Debra L. Bemis, Brian C. Stisser, Laurent Salomon, Mohamed A. Ghafar and Ralph Buttyan
Affiliation:
Keywords: prostate cancer, hypoxia, Hypoxia Inducible Factor, angiogenesis, vegf, apoptosis, akt/protein kinase b
Abstract: The accumulation of cancerous cells within a growing prostate tumor can deprive them of adequate vascular support. Without this support, the affected tumor cells become hypoxic, a condition that is usually unfavorable for the further growth and survival of eukaryotic cells. Mammalian cells, however, have the ability of responding to a hypoxic environment by activating a “hypoxia-response” signaling system. Ultimately, this signaling system upregulates the expression of a network of gene products that increase the propensity of the cell to survive even in this adverse environment. With increasing evidence that hypoxia and an activated hypoxia-response signaling system can influence progression (via increased angiogenic propensity and apoptotic resistance) and the therapeutic responsiveness of prostate cancer cells, this review will examine the concept of targeting hypoxia or the hypoxia-response system of prostate tumor cells as a means to suppress prostate tumor progression and metastasis or perhaps even as a means for eliminating prostate tumors in advanced prostate cancer patients
Export Options
About this article
Cite this article as:
Anastasiadis G. Aristotelis, Bemis L. Debra, Stisser C. Brian, Salomon Laurent, Ghafar A. Mohamed and Buttyan Ralph, Tumor Cell Hypoxia and the Hypoxia-Response Signaling System as a Target for Prostate Cancer Therapy, Current Drug Targets 2003; 4 (3) . https://dx.doi.org/10.2174/1389450033491136
DOI https://dx.doi.org/10.2174/1389450033491136 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Current Medicinal Chemistry Synthesis and Bioevaluation of Quaternary Centered 3-hydroxy-3 (alkynyl)indolin-2-one Derivatives as Potential Cytotoxic Agents and Akt Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Effect of Electric Field Intensity on Plasmid DNA/Membrane Interaction during In-Vitro Gene Electrotransfer
Drug Delivery Letters Energetics of Quadruplex-Drug Recognition in Anticancer Therapy
Current Cancer Drug Targets Density Functional Theory, Docking, Bioisosteric Replacement, Pharmacophore Perception, Physical Chemical Analyses of the Interactions of Novel PIM-1 Inhibitors with Suitable Pharmacokinetic Properties for Cancer Treatment
Current Physical Chemistry Angiogenesis Inhibition in the Treatment of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Current Perspectives on Anti-Aging Interventions
Letters in Drug Design & Discovery Macrocyclic Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Production of Retroviral Vectors: Review
Current Gene Therapy Pharmacokinetics of Darolutamide in Mouse - Assessment of the Disposition of the Diastereomers, Key Active Metabolite and Interconversion Phenomenon: Implications to Cancer Patients
Drug Metabolism Letters Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Current Pharmaceutical Design Carbon Nanotubes in the Treatment of Skin Cancers: Safety and Toxic ological Aspects
Pharmaceutical Nanotechnology Advances in Tumor Targeted Liposomes
Current Molecular Medicine Synthesis of 4-Arylaminoquinazolines from 2-amino-N'-Arylbenzamidines and Orthoesters via the Dimroth Rearrangement of Intermediate Quinazolin-4(3H)- Imines
Current Organic Chemistry Recent Advances in Small Molecule Prodrugs for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Imatinib Reduces the Vasculogenic Potential of Plastic Tumor Cells
Current Angiogenesis (Discontinued) Editorial [Hot topic: Prostate Cancer Therapy (Guest Editors: N. Sharifi and J.B. Aragon-Ching)]
Anti-Cancer Agents in Medicinal Chemistry Biological Relevance of DNA Polymerase Beta and Translesion Synthesis Polymerases to Cancer and its Treatment
Current Molecular Pharmacology Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases
MicroRNA Bench to Bedside Targeting of FLT3 in Acute Leukemia
Current Drug Targets